Global Gastrointestinal Stromal Tumor (GIST) Market Spotlight 2017-2026 – Clinical Trial Activity in the GIST Space is Dominated by Completed Trials – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Gastrointestinal Stromal Tumor (GIST)” report has
been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the gastrointestinal stromal tumor
(GIST) market, comprising key marketed and pipeline drugs, clinical
trials, key upcoming and regulatory events, patent information, a
10-year disease incidence forecast, and drug-specific revenue forecasts

Key Takeaways

• The report estimates that in 2017, there were 97,900 incident cases of
  gastrointestinal stromal tumor (GIST) worldwide, and expects that
  number to increase to 107,200 incident cases by 2026.
• Incidence rates (per 100,000) are highest in Asia and lowest in
  Northern America. The approved drugs in the GIST space target
  platelet-derived growth factor receptor, BCR-ABL fusion protein,
  vascular endothelial growth factor receptor, KIT/c-KIT, Raf kinase,
  and FMS-like tyrosine kinase 3. These therapies are administered via
  the oral route.
• The majority of the industry-sponsored drugs in active clinical
  development for GIST are in Phase II. Therapies in mid-to-late-stage
  development for GIST focus on a wide variety of targets. The majority
  of pipeline drugs in mid-to late-stage development are administered
  orally, with two drugs also being tested in intravenous formulations.
• High-impact upcoming events in the GIST space comprise topline Phase
  III trial results for DCC-2618 and topline Phase I/II trial results
  for ilixadencel.
• The overall likelihood of approval of a Phase I solid tumor asset is
  5.7%, and the average probability a drug advances from Phase III is
  39.4%. Drugs, on average, take 9.5 years from Phase I to approval,
  compared to 9.2 years in the overall oncology space.
• There has been only one licensing agreement involving GIST drugs
  during 2013-18. The exclusive collaboration and licensing agreement
  for $386m signed in June 2018 between Blueprint and CStone to develop
  and commercialize avapritinib, BLU-554, and BLU-667 in mainland China,
  Hong Kong, Macau, and Taiwan, either as monotherapies or combination
  therapies, was the only deal during the period.
• The clinical trials distribution across Phase I-IV indicates that the
  majority of trials for GIST have been in the early and midphases of
  development, with 83% of trials in Phase I-II and only 17% in Phase
  III-IV.
• The US has a substantial lead in the number of GIST clinical trials
  globally. France leads the major EU markets, while Japan has the top
  spot in Asia.
• Clinical trial activity in the GIST space is dominated by completed
  trials. Novartis has the highest number of completed clinical trials
  for GIST, with 63 trials. Novartis also leads industry sponsors with
  by far the highest number of overall clinical trials for GIST.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

Surgery

Targeted therapy

Other treatments

EPIDEMIOLOGY

MARKETED DRUGS

Approvals by country

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Avapritinib for GIST (November 15, 2018)

Iclusig for GIST (January 9, 2017)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Blueprint Lays Out Path To Early Approval In Small GIST Population

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

CStone Gains Rights To Blueprint’s Cancer Candidates

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/orujcq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs